{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:03:56Z","timestamp":1780409036221,"version":"3.54.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.4158\/ep.13.4.363","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T21:55:21Z","timestamp":1365198921000},"page":"363-372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Increase of Classic and Nonclassic Cardiovascular Risk Factors in Patients with Acromegaly"],"prefix":"10.1016","volume":"13","author":[{"given":"Lucio","family":"Vilar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Ansaneli","family":"Naves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Soares","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00eddia Freire","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Augusto","family":"Casulari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP.13.4.363_bb0005","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0002-9343(02)01094-X","article-title":"High output heart failure in patients with newly diagnosed acromegaly","volume":"112","author":"Damjanovic","year":"2002","journal-title":"Am J Med."},{"key":"10.4158\/EP.13.4.363_bb0010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1210\/er.2003-0009","article-title":"Cardiovascular function in acromegaly","volume":"24","author":"Clayton","year":"2003","journal-title":"Endocr Rev."},{"issue":"Suppl 4","key":"10.4158\/EP.13.4.363_bb0015","first-page":"31","article-title":"Cardiovascular disease and risk factors: the role of growth hormone","volume":"62","author":"Isgaard","year":"2004","journal-title":"Horm Res."},{"key":"10.4158\/EP.13.4.363_bb0020","first-page":"358","article-title":"The incidence and pathogenesis of hyperlipidaemia in 16 consecutive acromegalic patients","volume":"100","author":"Takeda","year":"1982","journal-title":"Acta Endocrinol (Copenh)."},{"key":"10.4158\/EP.13.4.363_bb0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0021-9150(96)06015-7","article-title":"LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I","volume":"129","author":"Tan","year":"1997","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP.13.4.363_bb0030","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/0026-0495(75)90129-8","article-title":"Serum lipids in acromegaly","volume":"24","author":"Nikkila","year":"1975","journal-title":"Metabolism."},{"key":"10.4158\/EP.13.4.363_bb0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1022101417810","article-title":"Therapy of dia betes and dyslipidemia in acromegaly","volume":"5","author":"Tamburrano","year":"2002","journal-title":"Pituitary."},{"key":"10.4158\/EP.13.4.363_bb0040","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev."},{"key":"10.4158\/EP.13.4.363_bb0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2265.2001.01218.x","article-title":"Growth hormone and the heart","volume":"54","author":"Colao","year":"2001","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP.13.4.363_bb0050","doi-asserted-by":"crossref","first-page":"537","DOI":"10.7326\/0003-4819-130-6-199903160-00021","article-title":"Lipoprotein(a) in acromegaly","volume":"130","author":"Maffei","year":"1999","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP.13.4.363_bb0055","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2265.2000.01092.x","article-title":"Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly","volume":"53","author":"Maldonado Castro","year":"2000","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP.13.4.363_bb0060","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0029-1211774","article-title":"Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I","volume":"105","author":"Wildbrett","year":"1997","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"10.4158\/EP.13.4.363_bb0065","first-page":"85","article-title":"Acromegaly treatment is associated with lower lipoprotein(a) and higher apolipoprotein A1 and low-density lipoprotein-cholesterol serum levels","volume":"3","author":"Naves","year":"2003","journal-title":"J Appl Res Clin Exp Ther."},{"key":"10.4158\/EP.13.4.363_bb0070","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0021-9150(99)00426-8","article-title":"LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients: effects of octreotide therapy","volume":"151","author":"Arosio","year":"2000","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP.13.4.363_bb0075","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/eje.0.1460303","article-title":"Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly","volume":"146","author":"Colao","year":"2002","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP.13.4.363_bb0080","series-title":"Carotid intima-media thickness (IMT), a marker of atherosclerosis, is not increased in patients with acromegaly [abstract]","first-page":"P1","article-title":"Presented at: 88th Annual Meeting of the Endocrine Society","author":"Paisley","year":"2006"},{"key":"10.4158\/EP.13.4.363_bb0085","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1210\/jc.2005-2857","article-title":"Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography","volume":"91","author":"Cannavo","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.13.4.363_bb0090","first-page":"441","article-title":"Impaired cardiac performance is a distinct feature of uncomplicated acromegaly","volume":"79","author":"Fazio","year":"1994","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.13.4.363_bb0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.13.4.363_bb0100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijcard.2005.01.068","article-title":"The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen","volume":"106","author":"Wilson","year":"2006","journal-title":"Int J Cardiol."},{"key":"10.4158\/EP.13.4.363_bb0105","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/oxfordjournals.aje.a008963","article-title":"Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial","volume":"144","author":"Kuller","year":"1996","journal-title":"Am J Epidemiol."},{"key":"10.4158\/EP.13.4.363_bb0110","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.13.4.363_bb0115","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker","year":"2002","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.13.4.363_bb0120","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1210\/jcem.87.4.8364","article-title":"Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant","volume":"87","author":"Sesmilo","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.13.4.363_bb0125","series-title":"Inflammatory markers, CRP and YKL-40, and the natriuretic peptide NT-ProBNP in acromegaly before and after treatment [abstract]","first-page":"P1","article-title":"Presented at: 88th Annual Meeting of the Endocrine Society","author":"Andreassen","year":"2006"},{"key":"10.4158\/EP.13.4.363_bb0130","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0167-5273(94)90207-0","article-title":"Haemostatic variables in patients with unstable angina","volume":"43","author":"Al-Nozha","year":"1994","journal-title":"Int J Cardiol"},{"key":"10.4158\/EP.13.4.363_bb0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/01.mbc.0000169220.00679.13","article-title":"Low normal level of protein C or of antithrombin increases risk for recurrent cardiovascular events","volume":"16","author":"Pelkonen","year":"2005","journal-title":"Blood Coagul Fibrinolysis."},{"key":"10.4158\/EP.13.4.363_bb0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2265.1997.d01-1743.x","article-title":"Elevated fibrinogen levels decrease following treatment of acromegaly","volume":"46","author":"Landin-Wilhelmsen","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP.13.4.363_bb0145","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1055\/s-2000-8145","article-title":"Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly","volume":"108","author":"Sartorio","year":"2000","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"10.4158\/EP.13.4.363_bb0150","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ecl.2006.06.005","article-title":"Molecular and signaling mechanisms of atherosclerosis in insulin resistance","volume":"35","author":"Schwartz","year":"2006","journal-title":"Endocrinol Metab Clin North Am."},{"key":"10.4158\/EP.13.4.363_bb0155","first-page":"526","article-title":"Criteria for cure of acromegaly: a consensus statement","volume":"85","author":"Giustina","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.13.4.363_bb0160","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.2337\/diacare.26.11.3160","article-title":"Follow-up report on the diagnosis of diabetes mellitus","volume":"26","author":"Genuth","year":"2003","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.13.4.363_bb0165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia."},{"key":"10.4158\/EP.13.4.363_bb0170","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.diabres.2005.10.017","article-title":"The threshold value for insulin resistance (HOMAIR) in an admixtured population IR in the Brazilian Metabolic Syndrome Study","volume":"72","author":"Geloneze","year":"2006","journal-title":"Diabetes Res Clin Pract."},{"key":"10.4158\/EP.13.4.363_bb0175","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"key":"10.4158\/EP.13.4.363_bb0180","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2005.02.080","article-title":"Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg\/dL and C-reactive protein <2 mg\/L: an analysis of the PROVE-IT TIMI-22 trial","volume":"45","author":"Ridker","year":"2005","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP.13.4.363_bb0185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11239-006-8081-0","article-title":"Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy","volume":"22","author":"Mega","year":"2006","journal-title":"J Thromb Thrombolysis."},{"key":"10.4158\/EP.13.4.363_bb0190","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijcard.2006.03.011","article-title":"Differences in inflammatory and thrombotic markers between unstable angina and acute myocardial infarction","volume":"115","author":"Tousoulis","year":"2007","journal-title":"Int J Cardiol."},{"key":"10.4158\/EP.13.4.363_bb0195","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [erratum in JAMA. 2003;290:197]","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA."},{"key":"10.4158\/EP.13.4.363_bb0200","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2265.2001.01256.x","article-title":"Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly","volume":"54","author":"Colao","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP.13.4.363_bb0205","first-page":"4","article-title":"The signifi cance of low-density-lipoproteins size in vascular diseases","volume":"25","author":"Rizzo","year":"2006","journal-title":"Int Angiol."},{"key":"10.4158\/EP.13.4.363_bb0210","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.STR.0000222666.21482.b6","article-title":"Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study","volume":"37","author":"Ohira","year":"2006","journal-title":"Stroke."},{"key":"10.4158\/EP.13.4.363_bb0215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.disamonth.2006.01.002","article-title":"Elevated lipoprotein(a)\u2014a genetic risk factor for premature vascular disease in people with and without standard risk factors: a review","volume":"52","author":"Enas","year":"2006","journal-title":"Dis Mon."},{"key":"10.4158\/EP.13.4.363_bb0220","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0021-9150(93)90189-2","article-title":"Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly","volume":"104","author":"Lam","year":"1993","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP.13.4.363_bb0225","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2265.1994.tb01825.x","article-title":"Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy","volume":"41","author":"Oscarsson","year":"1994","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP.13.4.363_bb0230","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/eje.0.1360377","article-title":"Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a)","volume":"136","author":"Laron","year":"1997","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP.13.4.363_bb0235","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1210\/jcem-27-10-1418","article-title":"Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment","volume":"27","author":"Sonksen","year":"1967","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.13.4.363_bb0240","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1590\/S0100-879X2001001100009","article-title":"Risk factors for glucose intolerance in active acromegaly","volume":"34","author":"Kreze","year":"2001","journal-title":"Braz J Med Biol Res."},{"key":"10.4158\/EP.13.4.363_bb0245","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1563-2571.2000.00106.x","article-title":"Prevalence of diabetes in acromegaly and Cushing syndrome [article in German]","volume":"27","author":"Biering","year":"2000","journal-title":"Acta Med Austriaca."},{"key":"10.4158\/EP.13.4.363_bb0250","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1055\/s-2007-1013498","article-title":"Elevation of high density lipoproteins in acromegalics after lisuride treatment","volume":"17","author":"Hainer","year":"1985","journal-title":"Horm Metab Res."},{"key":"10.4158\/EP.13.4.363_bb0255","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/BF03345216","article-title":"Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues","volume":"26","author":"Ronchi","year":"2003","journal-title":"J Endocrinol Invest."},{"key":"10.4158\/EP.13.4.363_bb0260","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2174\/156652406778018680","article-title":"Metabolic syndrome and diabetic atherothrombosis: implications in vascular complications","volume":"6","author":"Meerarani","year":"2006","journal-title":"Curr Mol Med."},{"issue":"Suppl A","key":"10.4158\/EP.13.4.363_bb0265","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.ghir.2006.03.006","article-title":"Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy","volume":"16","author":"Colao","year":"2006","journal-title":"Growth Horm IGF Res"},{"key":"10.4158\/EP.13.4.363_bb0270","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1530\/eje.1.02125","article-title":"Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency","volume":"154","author":"Bollerslev","year":"2006","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP.13.4.363_bb0275","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1210\/jcem.86.12.8087","article-title":"Inflammatory cardiovascular risk markers in women with hypopituitarism","volume":"86","author":"Sesmilo","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.13.4.363_bb0280","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.hjh.0000222754.75196.5c","article-title":"Hyperhomocysteinemia predicts total and cardiovascular mortality in high-risk women","volume":"24","author":"Rossi","year":"2006","journal-title":"J Hypertens."},{"issue":"6 Suppl","key":"10.4158\/EP.13.4.363_bb0285","doi-asserted-by":"crossref","first-page":"1741S","DOI":"10.1093\/jn\/136.6.1741S","article-title":"Pathophysiological consequences of homocysteine excess","volume":"136","author":"Jakubowski","year":"2006","journal-title":"J Nutr."},{"key":"10.4158\/EP.13.4.363_bb0290","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1001\/jama.288.16.2015","article-title":"Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis","volume":"288","year":"2002","journal-title":"JAMA."},{"key":"10.4158\/EP.13.4.363_bb0295","first-page":"811","article-title":"Homocysteine levels in acromegaly patients","volume":"26","author":"Hekimsoy","year":"2005","journal-title":"Neuro Endocrinol Lett."},{"key":"10.4158\/EP.13.4.363_bb0300","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jcem.87.7.8573","article-title":"Cardiovascular consequences of early-onset growth hormone excess","volume":"87","author":"Colao","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.13.4.363_bb0305","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajh.20546","article-title":"Roles of protein C, protein S, and antithrombin III in acute leukemia","volume":"81","author":"Dixit","year":"2006","journal-title":"Am J Hematol."},{"key":"10.4158\/EP.13.4.363_bb0310","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/clinchem\/47.9.1597","article-title":"Laboratory investigation of thrombophilia","volume":"47","author":"Tripodi","year":"2001","journal-title":"Clin Chem."},{"key":"10.4158\/EP.13.4.363_bb0315","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/153857440503900201","article-title":"Hypercoagulable states: a review","volume":"39","author":"Johnson","year":"2005","journal-title":"Vasc Endovascular Surg."},{"key":"10.4158\/EP.13.4.363_bb0320","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/eje.0.1480193","article-title":"Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly","volume":"148","author":"Jaffrain-Rea","year":"2003","journal-title":"Eur J Endocrinol."},{"issue":"1-2","key":"10.4158\/EP.13.4.363_bb0325","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cccn.2004.09.022","article-title":"Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity","volume":"352","author":"Wiesli","year":"2005","journal-title":"Clin Chim Acta."},{"key":"10.4158\/EP.13.4.363_bb0330","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","article-title":"Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance","volume":"154","author":"Colao","year":"2006","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP.13.4.363_bb0335","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1365-2265.2005.02273.x","article-title":"The effect of atorvastatin on serum lipoproteins in acromegaly","volume":"62","author":"Mishra","year":"2005","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP.13.4.363_bb0340","first-page":"293","article-title":"An audit of outcome of treatment in acromegaly","volume":"86","author":"Bates","year":"1993","journal-title":"Q J Med."},{"key":"10.4158\/EP.13.4.363_bb0345","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in acromegaly","volume":"89","author":"Holdaway","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.13.4.363_bb0350","first-page":"2730","article-title":"Mortality and cancer incidence in acromegaly: a retrospective cohort study","volume":"83","author":"Orme","year":"1998","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20418531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20418531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/68JX7U47M386TP8N.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:47:17Z","timestamp":1761515237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20418531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S1530891X20418531"],"URL":"https:\/\/doi.org\/10.4158\/ep.13.4.363","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increase of Classic and Nonclassic Cardiovascular Risk Factors in Patients with Acromegaly","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.13.4.363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}